Legal & General Group Plc Acquires 126,215 Shares of Integra LifeSciences Holdings Corporation $IART

Legal & General Group Plc increased its holdings in Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 52.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 368,947 shares of the life sciences company’s stock after purchasing an additional 126,215 shares during the period. Legal & General Group Plc’s holdings in Integra LifeSciences were worth $4,582,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the business. Systematic Financial Management LP boosted its holdings in Integra LifeSciences by 4.5% in the fourth quarter. Systematic Financial Management LP now owns 1,108,599 shares of the life sciences company’s stock worth $13,769,000 after purchasing an additional 48,094 shares in the last quarter. Global Retirement Partners LLC bought a new stake in Integra LifeSciences in the fourth quarter worth $25,000. Tejara Capital Ltd boosted its holdings in Integra LifeSciences by 42.6% in the fourth quarter. Tejara Capital Ltd now owns 171,813 shares of the life sciences company’s stock worth $2,134,000 after purchasing an additional 51,300 shares in the last quarter. Comerica Bank boosted its holdings in Integra LifeSciences by 14.6% in the fourth quarter. Comerica Bank now owns 65,946 shares of the life sciences company’s stock worth $819,000 after purchasing an additional 8,417 shares in the last quarter. Finally, UBS Group AG boosted its holdings in Integra LifeSciences by 211.7% in the fourth quarter. UBS Group AG now owns 408,969 shares of the life sciences company’s stock worth $5,079,000 after purchasing an additional 277,745 shares in the last quarter. 84.78% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on IART shares. Argus reiterated a “hold” rating on shares of Integra LifeSciences in a report on Wednesday, April 15th. Truist Financial decreased their price target on shares of Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating for the company in a report on Wednesday, April 15th. Citigroup upgraded shares of Integra LifeSciences from a “sell” rating to a “neutral” rating and upped their price target for the company from $11.00 to $16.00 in a report on Thursday, May 28th. Weiss Ratings upgraded shares of Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, May 13th. Finally, Wall Street Zen upgraded shares of Integra LifeSciences from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Four investment analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Reduce” and a consensus price target of $14.00.

Integra LifeSciences Stock Down 0.3%

Shares of IART opened at $16.94 on Tuesday. The company has a 50-day simple moving average of $12.62 and a 200-day simple moving average of $12.03. The firm has a market capitalization of $1.32 billion, a P/E ratio of -2.62, a P/E/G ratio of 1.18 and a beta of 1.24. The company has a debt-to-equity ratio of 1.75, a quick ratio of 1.95 and a current ratio of 3.38. Integra LifeSciences Holdings Corporation has a 52 week low of $8.70 and a 52 week high of $17.83.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings data on Tuesday, May 5th. The life sciences company reported $0.54 EPS for the quarter, beating analysts’ consensus estimates of $0.41 by $0.13. The business had revenue of $391.92 million during the quarter, compared to analyst estimates of $381.81 million. Integra LifeSciences had a negative net margin of 30.15% and a positive return on equity of 17.42%. The firm’s revenue for the quarter was up 2.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.41 earnings per share. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. On average, equities research analysts expect that Integra LifeSciences Holdings Corporation will post 2.44 earnings per share for the current year.

Integra LifeSciences Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.